Direct antilymphoma activity of novel, first-generation "antibody mimics" that bind HLA-DR10-positive non-Hodgkin's lymphoma cells

Cancer Biotherapy and Radiopharmaceuticals

Volumn 21, Issue 6, 2006, Pages 645-654

  West, Jeremy ^a   Perkins, Julie ^b   Hok, Saphon ^b   Balhorn, Rodney ^b   Lightstone, Felice C ^b   Cosman, Monique ^b   DeNardo, Sally J ^a   DeNardo, Gerald L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b LAWRENCE LIVERMORE NATIONAL LABORATORY   (United States)

Author keywords

Antibody; Bioactivity; Lymphoma; Radionuclide

Indexed keywords

AMINE; CARBOXYL GROUP; CELL SURFACE PROTEIN; DEOXYCHOLIC ACID; DIMER; HLA DR ANTIGEN; HLA DR10 ANTIGEN; LEUCINE ENKEPHALIN; LIGAND; LIOTHYRONINE; LYSINE; MACROGOL; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY LYM 1; RADIOISOTOPE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; CANCER INHIBITION; CELL DEATH; CELL MEMBRANE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG CYTOTOXICITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; IN VITRO STUDY; LYMPHOMA CELL; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BIOMIMETIC MATERIALS; CELL LINE, TUMOR; CELL SURVIVAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; HLA-DR ANTIGENS; HUMANS; LIGANDS; LYMPHOMA, NON-HODGKIN; STREPTAVIDIN;

EID: 33846642023     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2006.21.645     Document Type: Article

References (31)

1. McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program. J Clin Oncol 1998;16:2825.
2. Epstein AL, Marder RJ, Winter JN, et al. Two new monoclonal antibodies, Lym-1 and Lym-2, reactive with human B-lymphocytes and derived tumors, with immunodiagnostic and immunotherapeutic potential. Cancer Res 1987;47:830.
3. Rose LM, Deng CT, Scott S, et al. Critical Lym-1 binding residues on polymorphic HLA-DR molecules. Mol Immunol 1999;36:789.
4. Press OW, Fan AG, Borroz KI, et al. Endocytosis and degradation of monoclonal antibodies targeting human B-cell malignancies. Cancer Res 1989;49:4906.
5. Liu C, DeNardo GL, Tobin E, et al. Antilymphoma effects of anti-HLA-DR and CD20 monoclonal antibodies (Lym-1 and rituximab) on human lymphoma cells. Cancer Biother Radiopharm 2004;19:545.
6. Ottonello L, Morone P, Dapino P, et al. Monoclonal Lym-1 antibody-dependent lysis of B-lymphoblastoid tumor targets by human complement and cytokine-exposed mononuclear and neutrophilic polymorphonuclear leukocytes. Blood 1996;87:5171.
7. 131I-Lym-1. Cancer Res 1990;50(Suppl.):1014.
8. 67Cu-2IT-BAT-Lym-1 for fractionated radioimmunotherapy of non-Hodgkin's lymphoma: A pilot study. Anticancer Res 1998;18:2779.
9. DeNardo GL, DeNardo SJ, O'Donnell RT, et al. Are radiometal-labeled antibodies better than iodine-131-labeled antibodies: Comparative pharmacokinetics and dosimetry of copper-67-, iodine-131-, and yttrium-90-labeled Lym-1 antibody in patients with non-Hodgkin's lymphoma. Clin Lymph 2000;1:1:118.
10. 111In-2IT-BAD-Lym-1 in patients with non-Hodgkin's lymphoma. J Nucl Med 2000;41:952.
11. 131I-Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin's lymphoma. J Clin Oncol 1998;16:3246.
12. Press OW, Eary JF, Appelbaum FR, et al. Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N Engl J Med 1993;329:1219.
13. Balhorn R, Perkins SJ, Burke PA, et al. Development of synthetic high-affinity ligands that bind to a structural epitope on the tumor-cell receptor HLA-DR10. Proc Am Assoc Cancer Res 2005;46:902.
14. Rose LM, Gunasekera AH, DeNardo SJ, et al. Lymphoma-selective antibody Lym-1 recognizes a discontinuous epitope on the light chain of HLA-DR10. Cancer Immunol Immunother 1996;43:26.
15. DeNardo GL, Sysko VV, DeNardo SJ. Cure of Incurable Lymphoma. Int J Radiat Oncol Biol Phys 2006;66:S46.
16. Available Chemical Directory. Online document at: [AU: Retrieval date of Ref 16 URL?] 〈http://www. mdli.com/products/experiment/available_chem_dir/ index.jsp〉
17. Balhorn R, Perkins SJ, Burke PA, et al. Development of selective high-affinity ligand (SHAL) antibody mimics for lymphoma/leukemia imaging and therapy. Cancer Biother Radiopharm 2004;19:517.
18. Lu YA, Felix AM. Pegylated peptides. II. Solid-phase synthesis of amino-, carboxy-, and side-chain pegylated peptides. Int J Pept Protein Res 1994;43:127.
19. Chang CD, Meienhofer J. Solid-phase peptide synthesis using mild base cleavage of N alpha-fluoroenyl-methyloxycarbonylamino acids, exemplified by a synthesis of dihydrosomatostatin. Int J Pept Protein Res 1978;11:246.
20. Scatchard G. The attraction of proteins for small molecules and ions. Ann N Y Acad Sci 1947;51:660.
21. Hu E, Epstein AL, Naeve GS, et al. A phase 1a clinical trial of Lym-1 monoclonal antibody serotherapy in patients with refractory B-cell malignancies. Hematol Oncol 1989;7:155.
22. Shi XB, Gumerlock PH, Kroger LA, et al. Efficient recombination of Lym-1 scFv gene using multiple doubly restricted DNA fragments. Cancer Biother Radiopharm 1999;14:139.
23. Fernandez EM, O'Toole PJ, Morrison IEG, et al. Interaction of HLA-DR with actin microfilaments. Hum Pathol 2003;64:327.
24. Cosman M, Lightstone FC, Krishnan VV, et al. Identification of novel small molecules that bind to two different sites on the surface of tetanus Toxin C fragment. Chem Res Toxicol 2002;15:1218.
25. Jencks WP. What everyone wanted to know about tight binding and enzyme catalysis, but never thought of asking. Mol Biol Biochem Biophys 1980;32:3.
26. Hajduk PJ, Meadows RP, Fesik SW. Discovering high-affinity ligands for proteins. Science 1997;278:497.
27. Singer SJ, Nicolson GL. The fluid mosaic model of the structure of cell membranes. Science 1972;175:720.
28. Klemm JD, Schreiber SL, Crabtree GR. Dimerization as a regulatory mechanism in signal transduction. Annu Rev Immunol 1998;16:569.
29. Lane PJ, McConnell FM, Schieven GL, et al. The role of class II molecules in human B-cell activation. J Immunol 1990;144:3684.
30. St-Pierre Y, Nabavi N, Ghogawala Z, et al. A functional role for signal transduction via the cytoplasmic domains of MHC class II proteins. J Immunol 1989;143:808.
31. Arkin MR, Wells JA. Small molecule inhibitors of protein-protein interactions: Progressing towards the dream. Nat Rev Cancer 2004;3:301.